Recent Expansion CTI BioPharma, in partnership with Sobi group, has expanded its rare disease treatments to new markets, such as Australia, New Zealand, Korea, and Eastern Europe. This geographical diversification presents potential sales opportunities for the company's innovative medicines in these regions.
Strategic Partnerships The collaboration between CTI BioPharma and Sobi group signifies a strategic alignment to introduce Sobi's rare disease treatments to the Korean market through a joint venture. This strategic partnership opens avenues for sales growth and market penetration in the pharmaceutical sector in Korea.
Key Personnel Acquisition CTI BioPharma's appointment of Lydia Abad-Franch as Chief Medical Officer brings valuable expertise and leadership to the company. Leveraging her experience, CTI BioPharma can enhance its product positioning and sales strategies, potentially increasing market share and revenue.
Merger with CTI BioPharma The recent merger with CTI BioPharma Corp, valued at $1.7 billion, demonstrates a significant investment in the biopharmaceutical sector. This merger expands CTI BioPharma's portfolio to include blood-related cancers and rare diseases, creating new sales opportunities and revenue streams.
Financial Strength With revenue estimated between $10 million and $50 million, and funding of $50 million, CTI BioPharma is in a financially stable position to drive sales initiatives and expand market presence. The company's robust financial health provides a solid foundation for pursuing new sales partnerships and growth opportunities.
702
$100M$1B
595$50M$100M
14$10M
47$10M
51$10MCTI BioPharma uses 8 technology products and services including Optimise, SAS, Microsoft 365, and more. Explore CTI BioPharma's tech stack below.
| CTI BioPharma Email Formats | Percentage |
| FLast@ctibiopharma.com | 94% |
| Last@ctibiopharma.com | 4% |
| First.Last@ctibiopharma.com | 1% |
| FirstLast@ctibiopharma.com | 1% |
| First.Last@sobi.com | 98% |
| First.MiddleLast@sobi.com | 1% |
| FirstMiddle.Last@sobi.com | 1% |
Biotechnology ResearchWashington, United States51-200 Employees
We have merged with Sobi AB creating a biopharma company positioned to provide innovative medicines that transform the lives of people with rare and debilitating diseases. Visit www.sobi.com to continue to learn more about our work. For more information on the acquisition, see our press release at: https://bit.ly/42XKW9M
Company Overview
Funding & FinancialsCTI BioPharma has raised a total of $50M of funding over 8 rounds. Their latest funding round was raised on Aug 25, 2021 in the amount of $50M.
CTI BioPharma's revenue is in the range of $10M$50M
Funding & FinancialsCTI BioPharma has raised a total of $50M of funding over 8 rounds. Their latest funding round was raised on Aug 25, 2021 in the amount of $50M.
CTI BioPharma's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com